Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902011 | 0.88 | CACNA1B (0.53) | NPC1RAB9AHDAC2ALDH1A1KDM4E | |
| SCHEMBL13902003 | 0.80 | NPC1 (0.53) | NPC1RAB9ATP53KDM4EMAPT | |
| SCHEMBL13902006 | 0.77 | L3MBTL1 (0.60) | RAB9AALDH1A1TP53KDM4EMAPT | |
| SCHEMBL13902009 | 0.76 | GAA (0.41) | NPC1RAB9AALDH1A1 | |
| SCHEMBL2979461 | 0.76 | CFTR (0.56) | ADORA3 | |
| SCHEMBL30008296 | 0.70 | POLB (0.67) | NPC1RAB9AHDAC2ALDH1A1MDM4 | |
| SCHEMBL6170575 | 0.70 | POLB (0.67) | NPC1RAB9AHDAC2ALDH1A1MDM4 | |
| SCHEMBL1968036 | 0.70 | NPC1 (0.62) | NPC1RAB9AALDH1A1KDM4EMAPT | |
| SCHEMBL18628852 | 0.69 | MAPT (0.49) | NPC1RAB9AHDAC2MDM4TP53 | |
| SCHEMBL1110180 | 0.68 | MDM4 (0.73) | NPC1RAB9AHDAC2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | NPC1 795/4885RAB9A 1496/4885HDAC2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.